Biobank for Cholestatic Liver Diseases

Overview

About this study

This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

PSC

- Patients diagnosed with PSC and who are between the age of 18 and 85 at time of
enrollment in the study.

- The diagnosis of PSC will be based on standard PSC criteria including clinical and
biochemical evidence of chronic cholestasis of at least six months duration, positive
cholangiographic findings, and compatible liver biopsies if available.

- Patients with PSC who have undergone orthotopic liver transplantation will be offered
enrollment except for collection of bile - please see below under Exclusion Criteria.

- Women with PSC of childbearing potential and pregnant women will be offered enrollment
because there is no risk to an unborn child in this investigation.

PBC

- Patients diagnosed with PBC and who are between the age of 18 and 85 at time of
enrollment in the study.

- The diagnosis of PBC will be based on standard PBC criteria including clinical and
biochemical evidence of chronic cholestasis of at least six month duration, positive
anti-mitochondrial antibodies in serum and compatible liver biopsies, if available.

- Patients with PBC who have undergone orthotopic liver transplantation will be offered
enrollment except for collection of bile - please see below under Exclusion Criteria.

- Women with PBC of childbearing potential and pregnant women will be offered enrollment
because there is no risk to an unborn child in this investigation.

Controls

- Controls without history of PBC, PSC, or evidence of other chronic liver disease of
either gender that participate in this study will be between the ages of 18 and 85.

Liver Disease Controls

- Patients without history of PBC or PSC but do have evidence of other chronic liver
disease of either gender will be offered participation in this study if between the
ages of 18 and 85.

Exclusion Criteria (all subjects):

- PBC or PSC patients with known and overlapping other chronic liver diseases

- Patients unable to provide informed consent

- Prisoners and institutionalized individuals

Exclusion Criteria (for bile collection during ERCP)

- PSC with orthotopic liver transplantation

- History of Roux en Y

 

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 6/15/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Konstantinos Lazaridis, M.D.

Open for enrollment

Contact information:

Erik Schlicht CCRP

(507)284-4312

Schlicht.Erik@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20306562

Mayo Clinic Footer